scholarly journals Medicinal plants and their Anti-inflammatory effects in Hepatic disorders

2020 ◽  
Vol 1 (2) ◽  
Author(s):  
Muhammad Jahangeer ◽  
Zahed Mahmood ◽  
Zainab Khursheed ◽  
Mehvish Ashiq ◽  
Usman Ali ◽  
...  
Keyword(s):  
Liver Disease ◽  
Medicinal Plants ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Liver Diseases ◽  
Research Work ◽  
Herbal Medicines ◽  
Alcoholic Fatty Liver ◽  
Carcinogenic Effects ◽  
Alcoholic Fatty Liver Disease

Herbal medicines are used as an alternative treatment to cure liver diseases and now a days become most commonly used therapy. Herbal medicines are derived from different parts of plants such as bark, roots, leaves, seeds and flowers. Silymarin, Glycyrrhizic acid, Camellia sinensis, Holy Basil and Long pepper are the medicinal plants that are effective and safe for the treatment of liver ailments. Almost 2 million deaths per year occur due to liver diseases while correct Statistics for liver diseases is not available but liver diseases are highly prevalent in Africa and Asia. By using medicinal plants, the prevalence of hepatitis, alcoholic fatty liver disease, non-alcoholic fatty liver disease, liver cirrhosis and hepatocellular carcinoma can be controlled. The increase in use of herbal medicines support the phenomenon of their effectiveness for the prevention of liver disorders. Scientists are now finding the benefits and evaluate the effect of different herbs on human health by using the scientific methods. Further research work should be done on herbal medicines to collect relevant data about effectiveness and safety of herbs that are used in pharmaceuticals as additional components now a days. This article discusses the common liver diseases, categories of herbs, WHO estimated prevalence of liver diseases worldwide and carcinogenic effects of herbal medicines associated with liver injury.

scholarly journals The Evaluation of Drug Delivery Nanocarrier Development and Pharmacological Briefing for Metabolic-Associated Fatty Liver Disease (MAFLD): An Update

2021 ◽  
Vol 14 (3) ◽  
pp. 215
Author(s):  
Reem Abou Assi ◽  
Ibrahim M. Abdulbaqi ◽  
Chan Siok Yee
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Synergistic Effects ◽  
Herbal Medicines ◽  
Alcoholic Fatty Liver ◽  
Intrahepatic Lipids ◽  
Inflammatory Processes ◽  
Drug Compound ◽  
Alcoholic Fatty Liver Disease

Current research indicates that the next silent epidemic will be linked to chronic liver diseases, specifically non-alcoholic fatty liver disease (NAFLD), which was renamed as metabolic-associated fatty liver disease (MAFLD) in 2020. Globally, MAFLD mortality is on the rise. The etiology of MAFLD is multifactorial and still incompletely understood, but includes the accumulation of intrahepatic lipids, alterations in energy metabolism, insulin resistance, and inflammatory processes. The available MAFLD treatment, therefore, relies on improving the patient’s lifestyle and multidisciplinary pharmacotherapeutic options, whereas the option of surgery is useless without managing the comorbidities of the MAFLD. Nanotechnology is an emerging approach addressing MAFLD, where nanoformulations are suggested to improve the safety and physicochemical properties of conventional drugs/herbal medicines, physical, chemical, and physiological stability, and liver-targeting properties. A wide variety of liver nanosystems were constructed and delivered to the liver, only those that addressed the MAFLD were discussed in this review in terms of the nanocarrier classes, particle size, shape, zeta potential and offered dissolution rate(s), the suitable preparation method(s), excipients (with synergistic effects), and the suitable drug/compound for loading. The advantages and challenges of each nanocarrier and the focus on potential promising perspectives in the production of MAFLD nanomedicine were also highlighted.

Liver disease

2019 ◽  
pp. 367-384
Author(s):  
Nina Vodošek Hojs ◽  
Aftab Ala ◽  
Debasish Banerjee
Keyword(s):  
Cardiovascular Disease ◽  
Liver Disease ◽  
Hepatitis C ◽  
Fatty Liver ◽  
Viral Hepatitis ◽  
Liver Dysfunction ◽  
Fatty Liver Disease ◽  
Liver Diseases ◽  
Alcoholic Fatty Liver ◽  
Alcoholic Fatty Liver Disease

Cardiovascular disease in patients with liver disease, previously uncommon, is rising because of an increasing incidence of non-alcoholic fatty liver disease and better survival of patients with viral hepatitis, particularly hepatitis C. Liver dysfunction alters the pharmacokinetics and pharmacodynamics of many drugs, and hence careful use and dose adjustments are necessary. This chapter describes common cardiovascular conditions and the pharmacotherapy in patients with different liver diseases.

scholarly journals Diagnostic Accuracy of Serological Markers in Viral Hepatitis and Non Alcoholic Fatty Liver Disease. A Comparative Study in Tertiary Care Hospital of Western Nepal

1970 ◽  
Vol 1 (2) ◽  
pp. 60-63
Author(s):  
Ankush Mittal ◽  
Brijesh Sathian ◽  
Nishida Chandrasekharan ◽  
Akshay Lekhi ◽  
Shamim Mohammad Farooqui ◽  
...  
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Viral Hepatitis ◽  
Fatty Liver Disease ◽  
Liver Diseases ◽  
Serological Markers ◽  
Alcoholic Fatty Liver ◽  
Nonalcoholic Fatty Liver ◽  
Non Invasive ◽  
Alcoholic Fatty Liver Disease

Background: Liver diseases is apparently increasing and emerging as a major public health problem. Worldwide,  chronic hepatitis B has  become  the tenth leading cause of death  and  persons infected with chronic hepatitis B virus (HBV) and hepatitis C virus (HCV), are about 350 million and  125 million respectively. The aim of current retrospective comparative study was concerned primarily to evaluate the significance of non invasive serological markers for diagnosing liver diseases and their predictive implications in Pokhara valley. Materials and Methods: It was a hospital based retrospective study carried out using the data maintained in the Department of Biochemistry of the Manipal Teaching Hospital, Pokhara, Nepal between 1st June 2009 and 31st   October 2010.  The variables collected were total protein, albumin, AST, ALT, total bilirubin, direct bilirubin.  Descriptive statistics and testing of hypothesis were used for the analysis. Data was analyzed using EPI INFO and SPSS 16 software. Results: Of 515 subjects, 120 were suffering from viral hepatitis and 88 had non alcoholic fatty liver disease. In cases of viral hepatitis, mean values of AST (CI 730.65 to 902.68) and ALT (CI 648.14 to 847.59) were markedly increased as compared to controls. Mild to moderate elevations in serum levels of aspartate aminotransferase (CI 43.42 to 49.49), alanine aminotransferase (CI 43.90 to 53.92) were the most common laboratory abnormalities found in patients with nonalcoholic fatty liver disease. Conclusion: Non invasive tests have demonstrated a reasonable ability to identify significant fibrosis, cirrhosis in particular, nor is it surprising that liver disease specialists and patients favour a non invasive approach.Key words: Viral hepatitis; Nonalcoholic fatty liver disease; Nepal.DOI: http://dx.doi.org/10.3126/nje.v1i2.5137 Nepal Journal of Epidemiology 2011;1 (2):60-63

scholarly journals Helicobacter pylori infection and fatty liver

2020 ◽  
pp. 146-153
Author(s):  
A. S. Sarsenbaevа ◽  
K. A. Ufimtsev ◽  
E. V. Domracheva
Keyword(s):  
Helicobacter Pylori ◽  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Liver Diseases ◽  
Helicobacter Pylori Infection ◽  
Alcoholic Fatty Liver ◽  
Cancer Of The Stomach ◽  
The Subject ◽  
Alcoholic Fatty Liver Disease

Helicobacter pylori infection is widespread worldwide. It plays a signifi cant role in the pathogenesis of many diseases of the gastrointestinal tract, such as peptic ulcer, atrophic gastritis, and cancer of the stomach. Recently, a large number of works have appeared that indicate the association of Helicobacter pylori infection with extragastric diseases. Liver diseases, and especially fatty liver disease, are also widespread and actively studied. The association between Helicobacter pylori infection and non-alcoholic fatty liver disease has been the subject of many studies, but there is still insufficient evidence to make it clear.

An Evidence-based Study on Pharmacological Treatments of Non-Alcoholic Fatty Liver Disease Based on Traditional Persian Medicine

2020 ◽  
Vol 6 (3) ◽  
pp. 188-202
Author(s):  
Fatemeh Sadat Hasheminasab ◽  
Haleh Tajadini ◽  
Mohammad Setayesh
Keyword(s):  
Liver Disease ◽  
Medicinal Plants ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Current Evidence ◽  
Evidence Based ◽  
Alcoholic Fatty Liver ◽  
Persian Medicine ◽  
Traditional Persian Medicine ◽  
Alcoholic Fatty Liver Disease

Background: Non-Alcoholic Fatty Liver Disease (NAFLD) is one of the most prevalent liver diseases regarded as the primary cause of chronic liver disease, which may lead to hepatic failure. Despite the recent developments in the treatment of NAFLD, the necessity to find more efficient treatments has led to investigation on medicinal plants. Traditional Persian Medicine (TPM) is one of the oldest medical schools in the world. For treatment of NAFLD, different medicinal plants have been employed in TPM. Objective: Considering the public welcome for herbal medicines, the current evidence-based review study is conducted to investigate herbal remedies for NAFLD in TPM. Methods: Medicinal plants for treating NFALD were extracted according to three famous textbooks of Persian medicine. Then anti-obesity, hypolipidemic, hypoglycemic, antioxidative and hepatoprotective effects of these medicinal plants were investigated according to modern medicine. For this purpose, databases including Scopus, web of sciences, Pubmed, Google scholar and science direct were searched. Results: Investigations of Persian medicine textbooks resulted in deriving 53 herbs, which are useful for treating NAFLD. Searching through aforesaid databases showed that most of these plants can help to treat this disease in at least 2 ways. 25 herbs are effective in all 5 mentioned effects. Conclusion: It should be considered that in Persian medicine, first-line treatment is correction of life style, then if necessary, herbs are prescribed. However, this study showed that many herbs mentioned in Persian medicine for treatment of NAFLD might have a potential to aid patient with this disease.

Correlation between adiponectin level and the degree of fibrosis in patients with NAFLD

QJM ◽  
2021 ◽  
Vol 114 (Supplement_1) ◽  
Author(s):  
Tarek Mohammed Youssef ◽  
Manal Sabry Mohamed ◽  
Ahmed El-Metwally Ahmed ◽  
Esraa Ebrahim Abdullah
Keyword(s):  
Diabetes Mellitus ◽  
Liver Disease ◽  
Liver Fibrosis ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Liver Diseases ◽  
Adiponectin Level ◽  
Chronic Liver ◽  
Alcoholic Fatty Liver ◽  
Alcoholic Fatty Liver Disease

Abstract Background Non-alcoholic Fatty Liver Disease (NAFLD) is one of the most prevalent chronic liver diseases particularly in Egypt. It is defined as accumulation of lipids inside the hepatocytes, in absence of other etiologies of hepatic damage. It is frequently associated with obesity, diabetes mellitus and metabolic syndrome. Objective To find out the correlation between the degree of liver fibrosis in Non-alcoholic Fatty Liver Disease patients and their serum Adiponectin level as a future non-invasive method for assessment of liver fibrosis to substitute liver biopsy to avoid its hazardous complication. Also to study the correlation between diabetes mellitus as well as obesity and serum Adiponetctin level. Patients and Methods 50 patients were selected to participate in our study based on our inclusion criteria. They were recruited from the Internal Medicine department, Gastro-intestinal clinic in AlDemerdash Hospital using a convenient sampling method. Diagnoses of NAFLD (Non-alcoholic fatty liver disease) was confirmed by laboratory markers (AST, ALT, Lipid profile), ultrasound as well as fibroscan examination. Results Analyzing adiponectin levels showed that -besides its significant correlation with BMI, hypertension, diabetes mellitus and dyslipidemia- it was significantly lower in high grade fibrosis group compared to low grade fibrosis group with P-value of (0.000) and a cutoff value for stage 3/4 fibrosis of about 2.31μg/ml which marked a promising hope of adeponictin being of protective value against liver fibrosis. However, more studies performed on populations of different sizes and characteristics are recommended to allow more accurate generalization of the results and hopefully exploring a new horizon for the follow up and treatment of patients with chronic liver disease especially NAFLD. Conclusion Adiponectin is an abundant adipocyte-derived protein with well-established antiatherogenic, insulin-sensitizing and anti-inflammatory properties. The liver is a major target organ for adiponectin especially in fatty liver diseases and this adipocytokine has the ability to control many liver functions including metabolism, inflammation and fibrosis. Both serum levels and hepatic adiponectin receptor expression are decreased in NAFLD. Therefore, either adiponectin itself or adiponectin-inducing agents might be of key therapeutic interest in the near future in the treatment of NAFLD.

New opportunities for the correction of type 2 diabetes mellitus in patients with liver diseases

2021 ◽  
Author(s):  
Л.Ю. Моргунов ◽  
Х.С. Мамедгусейнов
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Liver Disease ◽  
Fatty Liver ◽  
Fatty Liver Disease ◽  
Liver Diseases ◽  
Alcoholic Fatty Liver ◽  
Alcoholic Fatty Liver Disease

Заболевания печени у пациентов с сахарным диабетом 2 типа встречаются с большей частотой, чем в общей популяции. Сахарный диабет 2-го типа оказывает негативное влияние на состояние печени, нарушая обмен белков, аминокислот, жиров и других веществ в гепатоцитах, что ведет к развитию ее хронических заболеваний. Сочетание патологии печени и сахарного диабета является прогностическим фактором осложнений и летального исхода. Ингибиторы натрий-глюкозного котранспортера 2-го типа (дапаглифлозин, эмпаглифлозин, канаглифлозин) оказывают позитивное влияние на уменьшение степени жирового гепатоза, снижение концентрации печеночных ферментов и активности воспалительного процесса в печени, улучшая гистологическую картину стеатоза и стеатогепатита. Прогрессирование изменений в печени при сахарном диабете 2 типа в виде неалкогольной жировой болезни печени, объединяющей неалкогольный стеатоз и неалкогольный стеатогепатит, имеющих общие механизмы с синдромом инсулинорезистентности, отражает этапы формирования заболеваний печени, приводящие в итоге к развитию ее цирроза. Проведенные исследования указывают на эффективность натрий-глюкозных котранспортеров 2-го типа у пациентов с циррозом печени. У пациентов с неалкогольной жировой болезнью печени и сахарным диабетом 2 типа при лечении ингибиторами натрий-глюкозного котранспортера 2-го типа отмечается улучшение гистопатологических характеристик при проведении биопсии печени. Кроме того, у этих пациентов наблюдалось снижение индекса массы тела, окружности талии, уровня гликемии. У больных сахарным диабетом 2 типа и неалкогольной жировой болезнью печени, подверженных повышенному риску развития цирроза печени, при лечении ингибиторами натрий-глюкозного котранспортера 2-го типа наблюдалось клинически значимое снижение уровня аланинаминотранферазы в сыворотке крови. Препараты хорошо переносятся пациентами с заболеваниями печени, безопасны в применении и могут с успехом использоваться у больных с печеночной недостаточностью. Liver diseases in patients with type 2 diabetes mellitus occur with a higher frequency than in the general population. Type 2 diabetes mellitus has a negative effect on the condition of the liver, disrupting the metabolism of proteins, amino acids, fats and other substances in hepatocytes, which leads to the development of its chronic diseases.The combination of liver pathology and diabetes mellitus is a prognostic factor of complications and death. Type 2 sodium-glucose cotransporter inhibitors (dapagliflozin, empagliflozin, kanagliflozin) have a positive effect on reducing the degree of fatty hepatosis, reducing the concentration of liver enzymes and the activity of the inflammatory process in the liver, improving the histological picture of steatosis and steatohepatitis. The progression of changes in the liver in type 2 diabetes mellitus in the form of nalcohol fatty liver disease, combining non-alcoholic steatosis and non-alcoholic steatohepatitis, which have common mechanisms with insulin resistance syndrome, reflects the stages of formation of liver diseases, resulting in the development of cirrhosis of the liver. The conducted studies indicate the effectiveness of type 2 sodium-glucose transporters in patients with cirrhosis of the liver. In patients with nnon-alcoholic fatty liver disease with type 2 diabetes mellitus, when treated with inhibitors SGLT2, there is an improvement in histopathological characteristics during liver biopsy. In addition, these patients had a decrease in body mass index, waist circumference, and glycemic level. in patients with type 2 diabetes mellitus and non-alcoholic fatty liver disease at increased risk of liver cirrhosis, a clinically significant decrease in serum alanine aminotransferase levels was observed during the treatment of inhibitors SGLT2.I шn patients with liver diseases, the drugs are well tolerated, safe to use and can be successfully used in patients with liver failure.

Sign in / Sign up

Export Citation Format

Share Document